Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.

Name: Αlpha¹ Rigor Record — Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
Item: Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
Rating: 59
Author: Αlpha¹

Patel PD, Liang Y, Meiring JE, Chasweka N, Patel P, Misiri T, Mwakiseghile F, Wachepa R, Banda HC, Shumba F, Kawalazira G, Dube Q, Nampota-Nkomba N, Nyirenda OM, Girmay T, Datta S, Jamka LP, Tracy JK, Laurens MB, Heyderman RS, Neuzil KM, Gordon MA, TyVAC team

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4★ (Strong), 0 critical, 3 high issues for “Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingStatistical analysis not met−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting inadequateAssessed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-designed and generally well-reported Phase 3 clinical trial with a strong scientific premise and robust ethical approvals. However, a critical arithmetic inconsistency in a key results table and the absence of reported baseline weight for a pediatric cohort slightly diminish its rigor. The lack of explicit reference to a reporting guideline also represents a minor reporting gap.

This review synthesized two independent rigor evaluations and a copyedit report. The reviewers largely agreed, with the main divergences concerning the completeness of biological variable reporting and the severity of the reporting guideline omission. The statistical analysis dimension's 'fail' status is driven by a clear arithmetic error identified by Reviewer 2, the integrity component, and the copyedit pass.

6 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 fail

The introduction and 'Research in context' sections cite extensive prior work, including Cochrane reviews and earlier efficacy trials, and explicitly note the gap in long-term durability data. The rationale for the study is logically derived from the cited evidence, and the paper discusses how the limitations of prior studies (e.g., short follow-up, lack of data in children under 2 years) are addressed in this trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper thoroughly establishes the scientific premise by citing prior research, clearly articulating the rationale for the study, and addressing limitations of previous work.

Evidence

direct quote[Introduction, paragraph 3]

“A Cochrane systematic review estimated that the efficacy of Vi-PS fell from 69% (95% CI 63–74) after 1 year to 55% (95% CI 30–70) after 3 years.”